Endometrial immune profiling and precision therapy increase live birth rate after embryo transfer: A randomised controlled trial

Nathalie LEDEE ^1* Marie Petitbarat ² Geraldine Dray ³ Chevrier Lucie ² Alaa Kazhalawi ² Mona Rahmati ⁴ Eric Vicaut ⁵ Abdourahmane Diallo ⁵ Nino Guy Cassuto ⁶ Lea Ruoso ⁶ Laura Prat-Ellenberg ³

• ¹ Université de Versailles Saint-Quentin-en-Yvelines, Versailles, Île-de-France, France
• ² MatriceLAB Innove, Paris, France
• ³ Maternité Des Bluets Hôpital Pierre Rouquès, Paris, France
• ⁴ London Women's Clinic, London, United Kingdom
• ⁵ Unité de Recherche Clinique, Hôpital Fernand Widal, (APHP), Université Paris-Diderot Paris 7,, Paris, France
• ⁶ Laboratoire Drouot, Paris, France

Introduction: Despite advancements in assisted reproductive treatments, 70% of transferred embryos fail to implant successfully, yielding significant global repercussions. One promising avenue of research is to take into account the individual's immune uterine profile in order to tailor treatment and optimize outcomes. This randomized controlled trial represents the initial exploration into the consequences of disregarding the state of the uterine immune environment in infertile women embarking on IVF/ICSI.This randomised controlled open two-arm trial included IVF patients, with assessment of immune endometrial environment and precision therapy before embryo transfer (ET). 493 patients were enrolled from October 2015 to February2023. Endometrial biopsies were collected during the mid-luteal phase. Endometrial immune profiling involves the analysis of cytokine biomarkers. If an immune endometrial dysregulation was diagnosed, a computerised randomisation assigned patients to either a conventional ET (disregarding the immune profile) or a personalised ET (with a precision therapy adapted to the immune profile). The primary analysis focused on demonstrating the superiority of precision care using the modified intent-to-treat population (mITT), excluding patients without ET. The primary endpoint was the live birth rate (LBR) following the ET.Results:78% had an endometrial immune dysregulation and were randomised. The mITT analysis showed a significant increase in LBR with precision care compared to conventional care (29.7% vs. 41.4%; OR: 1.68 [1.04-2.73], p=0.036). The positive impact of precision care was particularly noticeable in patients with morphologically suboptimal embryos (LBR: 21.2% vs. 39.6%; OR: 2.12 [1.02-4.41]) or those with a history of two or more failed ET (LBR: 23.4% vs. 48.1%; OR: 3.03 [1.17-7.85]).The data should be interpreted with caution due to inherent limitations of human IVF trials. Generalising our findings would rely on the replication of controlled trials by independent research teams possibly integrating the usage of optimised embryo quality with PGT-A.The regulation of the endometrial immune environment emerges as one of the leading innovative strategies to facilitate embryo implantation and enhance the overall performance of assisted reproductive therapies (ART). Based on these findings, endometrial immune profiling could become an essential part of routine ART practice.